Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor

Cogent Biosciences announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research 2024 Annual Meeting taking place in San Diego, California. Title: Characterization of a Novel Mutant Selective, EGFR Sparing, ErbB2 Inhibitor with Activity Across Activating Mutations in Systemic and CNS Tumors. Cogent is developing a potential best-in-class EGFR-sparing, brain-penetrant ErbB2 inhibitor that includes potent coverage of key mutations inadequately addressed by currently approved therapies. Activating mutations in the ErbB2 gene have been identified in multiple cancers and demonstrate a tumorigenic role similar to that of ErbB2 amplification. The poster presented today describes CGT4255’s exceptional stability in human whole blood and liver cytosol fractions and high oral bioavailability and low clearance across preclinical species. In addition, CGT4255 demonstrated 80% brain penetrance in mice and was well-tolerated at 10x concentration, resulting in mouse tumor regression, suggesting potential best-in class properties.